Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nasal spray before labor ward off postpartum depression?

NCT ID NCT07501728

Prevention Sponsor: Chengdu Jinjiang Maternity and Child Health Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of intranasal dexmedetomidine, given just before labor pain relief, can lower the chance of postpartum depression (PPD). Researchers will enroll 270 women having vaginal deliveries and randomly give them either the drug or a placebo. The main goal is to see if fewer women develop PDD symptoms 42 days after giving birth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine
What this could lead to
If it works, this could offer a simple, non-invasive way to lower the risk of postpartum depression after vaginal delivery.
What could go wrong
This is a small, early-stage trial (270 participants) testing a single dose. The effect may be modest or not statistically significant, and side effects like low heart rate or low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ASA physical status II or III. * Age ≥ 18 years. * Singleton pregnancy, cephalic presentation * No contraindications to neuraxial anesthesia and voluntarily requesting labor analgesia for planned vaginal delivery Exclusion Criteria: * History of bipolar disorder, psychiatric disorders, or suicidal ideation * Severe cardiac, cerebral, hepatic, or renal disease * Allergy to α2-adrenergic receptor agonists * Baseline bradycardia (heart rate \< 60 bpm) or cardiac conduction abnormalities before labor analgesia * Hypotension (systolic blood pressure \< 90 mmHg) before labor analgesia * History of drug or alcohol abuse * Severe rhinitis or nasal cavity deformity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum depression (PPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

postpartum depression prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum depression (PPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chengdu Jinjiang District Women & Children Health Hospital,

    Chengdu, Sichuan, 610011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.